Scienture jumps after expanding access to hypertension drug

Shares of  drugmaker Scienture Holdings SCNX.O rise 10.34% to $0.4993 premarket

 Co says it has expanded access to Arbli, its ready-to-use liquid losartan for high blood pressure

 Losartan treats hypertension, a condition where consistently high blood pressure increases the risk of stroke and heart disease - SCNX

 Co says Arbli now available at more than 2,500 healthcare sites, with coverage for 100 million insured Americans

Expects continued Arbli prescription growth in Q1 and wider insurance and pharmacy coverage

Says its nasal spray for opioid overdose emergencies, Rezenopy, is set for a U.S. launch in Q2 2026

Shares fell ~92% in 2025